GFM
CRVS icon

GF Fund Management’s Corvus Pharmaceuticals CRVS Stock Holding History

GF Fund Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.4K Buy
1,667
+201
+14% +$3.21K ﹤0.01% 475
2025
Q4 		$11.3K Sell
1,466
-137
-9% -$1.08K ﹤0.01% 564
2025
Q3 		$11.8K Buy
1,603
+9
+0.6% +$46 ﹤0.01% 540
2025
Q2 		$6.38K Hold
1,594
– – ﹤0.01% 612
2025
Q1 		$5.07K Buy
1,594
+245
+18% +$1.15K ﹤0.01% 623
2024
Q4 		$7.22K Buy
+1,349
New +$10.1K ﹤0.01% 584

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GF Fund Management's CRVS Position: Q1 2026 in Review

GF Fund Management increased its Corvus Pharmaceuticals (CRVS) stake by 14% in Q1 2026, buying an estimated $3.21K and bringing the position to 1,667 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #475.

GF Fund Management first reported a position in CRVS in Q4 2024 and has held it in 6 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • GF Fund Management held 1,667 shares of Corvus Pharmaceuticals worth $24.4K as of Q1 2026.
  • GF Fund Management bought 201 Corvus Pharmaceuticals shares in Q1 2026, an estimated $3.21K.
  • Corvus Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #475 holding.
  • GF Fund Management first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.